Cultivating resiliency in patients with neurofibromatosis 2 who are deafened or have severe hearing loss: a live‑video randomized control trial
Patients with NF2 who are deaf or have significant hearing loss face numerous and unique challenges which lead to poor quality of life, and thus may benefit from resiliency programs.
We performed secondary data analyses on a single blind, randomized controlled trial of an 8 week mind–body resiliency program (the Relaxation Response and Resiliency program for Deaf NF2; d3RP-NF2) versus a health education control (Health Enhancement Program for Deaf NF2;dHEP-NF2) which showed improvement in quality of life (Funes in JAMA 2019, https://doi.org/10.1007/s11060-019-03182-3). Here we report on improvements in resiliency factors (i.e. optimism, gratitude, perceived social support, mindfulness, and perceived coping abilities) assessed at baseline, post-test and 6-month follow-up. Both programs were delivered via Skype using Communication Access Real-Time Translation.
Patients who were randomized to the d3RP-NF2 program exhibited significant improvements from baseline to post-program in gratitude (Mdifference = 4.04, 95% CI 1.58–6.50; p = 0.002), perceived social support (Mdifference = 16.36, 95% CI 9.20–23.51; p < 0.001), mindfulness (Mdifference = 4.02, 95% CI 1.10–6.94; p = 0.008), perceived coping (Mdifference = 15.25, 95% CI 10.21–20.28; p < 0.001), and a non-significant trend of improvement in optimism (Mdifference = 1.15, 95% CI −0.14–12.44; p = 0.079). These improvements were all maintained through the 6-month follow up. Improvements in perceived coping (Mdifference = 12.34, 95% CI 4.75–19.93; p = 0.002), social support (Mdifference = 13.11, 95% CI 2.19–24.03; p = 0.02), and gratitude (Mdifference = 4.59, 95% CI 0.83–8.36; p = 0.018) were over and above the changes observed in those randomized to dHEP-NF2.
The d3RP-NF2 sustainably improves multiple dimensions of resiliency. Promoting resiliency may be of utmost importance for this uderserved population.
KeywordsNeurofibromatosis Deaf Resiliency Mind–body program Communication access real-time translation Videoconferencing
This study was possible due to a Clinical Trials Award from the Children’s Tumor Foundation (CTF) and a Department of Defense Grant (W81XWH-17–1-0121) to Ana-Maria Vranceanu.
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 3.Carver CS (2006) MOCS (Measure of current status). Retrieved 19 June 2019 https://www.psy.miami.edu/faculty/ccarver/sclMOCS.html
- 5.Feldman G, Hayes A, Kumar S, Greeson J, Laurenceau JP (2007) Mindfulness and emotion regulation: the development and initial validation of the Cognitive and Affective Mindfulness Scale-Revised (CAMS-R). J Psychopathol Behav Assess 29(3):177–190. https://doi.org/10.1007/s10862-006-9035-8 CrossRefGoogle Scholar
- 7.Funes CJ, Mace RA, Macklin EA, Plotkin SR, Jordan JT, Vranceanu AM (2019) First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial. J Neurooncol. https://doi.org/10.1007/s11060-019-03182-3 CrossRefPubMedGoogle Scholar
- 9.Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. https://doi.org/10.1016/j.jbi.2008.08.010 CrossRefPubMedGoogle Scholar
- 15.Mortel TF (2008) Faking it: social desirability response bias in self-report research. Aust J Adv Nurs 25(4):40–48Google Scholar
- 16.Neary WJ, Hillier VF, Flute T, Stephens SDG, Ramsden RT, Evans DGR (2010) The relationship between patients’ perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 35(4):291–299. https://doi.org/10.1111/j.1749-4486.2010.02176.x CrossRefPubMedGoogle Scholar
- 26.Vranceanu AM, Merker VL, Plotkin SR, Park ER (2014) The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study. J Neurooncol 120(1):103–109. https://doi.org/10.1007/s11060-014-1522-2 CrossRefPubMedGoogle Scholar